284 related articles for article (PubMed ID: 32053090)
1. PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.
Raal FJ; Chilton R; Ranjith N; Rambiritch V; Leisegang RF; Ebrahim IO; Tonder AV; Shunmoogam N; Bouharati C; Musa MG; Karamchand S; Naidoo P; Blom DJ
Endocr Metab Immune Disord Drug Targets; 2020; 20(6):840-854. PubMed ID: 32053090
[TBL] [Abstract][Full Text] [Related]
2. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
Nozue T
J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Wójcik C
Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
5. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
[TBL] [Abstract][Full Text] [Related]
6. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
7. Real-world use of PCSK9 inhibitors: A single-center experience.
Sarsam S; Berry A; Degheim G; Singh R; Zughaib M
J Int Med Res; 2019 Jan; 47(1):265-270. PubMed ID: 30280628
[TBL] [Abstract][Full Text] [Related]
8. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
[TBL] [Abstract][Full Text] [Related]
9. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
10. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
[TBL] [Abstract][Full Text] [Related]
11. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Achimastos A; Alexandrides T; Alexopoulos D; Athyros V; Bargiota A; Bilianou E; Chrysochoou C; Drogari E; Elisaf M; Ganotakis E; Goudevenos I; Ioannidis I; Kolovou G; Kotsis V; Lekakis I; Liberopoulos E; Melidonis A; Nikolaou V; Ntaios G; Papanas N; Pappas S; Pitsavos C; Rallidis L; Richter D; Skoumas I; Tentolouris N; Tousoulis D; Tselepis A; Tsioufis K; Tziakas D; Tziomalos K; Vardas P; Vlachopoulos C; Vlahakos D
Hormones (Athens); 2016; 15(1):8-14. PubMed ID: 27086681
[TBL] [Abstract][Full Text] [Related]
12. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
13. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
O'Keefe JH; DiNicolantonio JJ; Lavie CJ
Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.
Zhao Z; Du S; Shen S; Luo P; Ding S; Wang G; Wang L
Medicine (Baltimore); 2019 Feb; 98(6):e14400. PubMed ID: 30732185
[TBL] [Abstract][Full Text] [Related]
17. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Korman M; Wisløff T
Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
[TBL] [Abstract][Full Text] [Related]
18. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
19. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
Leong D; Wu PE
CMAJ; 2019 Aug; 191(32):E894. PubMed ID: 31405836
[No Abstract] [Full Text] [Related]
[Next] [New Search]
